Atamestane

Atamestane

Clinical data
Other names	SH-489; Metandroden; 1-Methylandrosta-1,4-diene-3,17-dione
Routes of administration	By mouth[1]
ATC code	None
Legal status
Legal status	UK: Class C
Identifiers
IUPAC name (8R,9S,10S,13S,14S)-1,10,13-Trimethyl-7,8,9,11,12, 14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione
JSmol)	Interactive image
SMILES O=C\1/C=C(/C)[C@]4(C(=C/1)/CC[C@@H]3[C@@H]4CC[C@@]2(C(=O)CC[C@H]23)C)C
InChI InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1 Y Key:PEPMWUSGRKINHX-TXTPUJOMSA-N Y
NY (what is this?)  (verify)

Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer.^[2] It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.^{[3][additional citation(s) needed]}

See also

• Boldione (androsta-1,4-diene-3,17-dione)

References